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Abstract
This paper reviews how epidemiological studies during the last 5 years have advanced our 
knowledge in addressing the global stroke epidemic. The specific objectives were to review the 
current evidence supporting management of ten major modifiable risk factors for prevention of 
stroke: hypertension, current smoking, diabetes, obesity, poor diet, physical inactivity, atrial 
fibrillation, excessive alcohol consumption, abnormal lipid profile and psychosocial stress/
depression.
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According to estimates by the WHO, stroke accounted for 5.7 million deaths and 16 million 
first-time events in 2005 and these numbers may reach 7.8 million and 23 million by 2030, 
respectively [1]. Stroke is the second leading cause of preventable death worldwide and the 
fourth leading cause of lost productivity [2], as measured by disability-adjusted life years. 
Evidence obtained from large epidemiological studies has revealed that the risk factors for 
stroke and their associations with stroke were similar in different parts of the world [3].
Several risk factors for stroke have been documented, mostly by studies conducted in high-
income countries [4]. Nonetheless, the 2009 standardized case–control INTERSTROKE 
study in 22 countries worldwide (Argentina, Australia, Brazil, Canada, Chile, China, 
Colombia, Croatia, Denmark, Ecuador, Germany, India, Iran, Malaysia, Mozambique, 
Nigeria, Peru, Philippines, Poland, South Africa, Sudan and Uganda) confirmed the 
significance of the same risk factors in low- and middle-income countries [3]. Results from 
this study found that hypertension, current smoking, diabetes, abdominal obesity, poor diet 
and physical inactivity accounted for more than 80% of the global risk of all types of stroke 
(ischemic and hemorrhagic); other risk factors included excessive alcohol consumption, 
dyslipidemia (measured by ratio of apolipoproteins B to A1), cardiac causes (atrial 
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fibrillation or flutter, previous myocardial infarction, rheumatic valvular heart disease and 
prosthetic heart valve) and psychosocial stress/depression [3].
The overall objectives of this article were to review how epidemiological studies during the 
last 5 years have advanced our knowledge in addressing the global stroke epidemic. The 
specific objectives were to review the current evidence supporting management of ten major 
modifiable risk factors for stroke.
Methods: search strategy & selection criteria
In the current article we have reviewed risk factors for stroke that were identified as leading 
risk factors in the INTERSTROKE study [3] and/or the recently issued Guidelines for the 
Primary Prevention of Stroke for Healthcare Professionals from the American Heart 
Association (AHA)/American Stroke Association (ASA) [4]: hypertension, current smoking, 
diabetes, atrial fibrillation, dyslipidemia, obesity, poor diet, physical inactivity, excessive 
alcohol consumption and psychosocial stress/depression. Excessive alcohol consumption 
and psychosocial stress/depression were considered by the AHA/ASA as less well-
documented risk factors for stroke [4] but we have included them in this review since they 
emerged as major risk factors for stroke in the INTERSTROKE study [3].
Eligibility criteria were as follows: only papers published in English in journals that were 
indexed in PubMed during the last 5 years were reviewed. We searched PubMed from 
January 2006 to 30 November, 2011, with the words “stroke”, “isch(a) emic stroke”, 
“intracerebral”, “intraparenchymal”, “subarachnoid”, “h(a)emorrhage” and “epidemiology”, 
“epidemiological”, “hypertension”, “high blood pressure”, “smoking”, “obesity”, “body 
mass index”, “waist circumference”, “waist-to-hip ratio”, “diet”, “fat”, “sodium”, “vitamin”, 
“physical inactivity”, “physical activity”, “exercise”, “diabetes”, “alcohol consumption”, 
“psychosocial stress”, “depression”, “apolipoproteins”, “lipoproteins”, “cholesterol”, “atrial 
fibrillation”, “meta-analysis” and “review”.
Hypertension
High blood pressure (BP) is the major risk factor for all stroke types with an estimated 
population-attributable fraction (PAF) ranging from 35 to 52%, depending on the definition 
of hypertension and stroke subtypes [3]. However, evidence suggests that the prevalence of 
risk factors and stroke types varies by region, gender and race ethnicity, thus resulting in 
differences in the estimated PAF. In the 2009 INTERSTROKE study, compared with 
participants without hypertension, participants with hypertension (self-reported hypertension 
or BP >160/90 mmHg) were 2.8 times more likely to have a stroke [3]. Stronger associations 
between stroke and hypertension were found in individuals younger than 45 years than in 
those aged 45 years or older (odds ratios 8.5 vs 3.9, respectively). Current evidence indicates 
substantial benefits of reducing BP for the prevention of stroke. The results from the 2009 
meta-analysis of clinical trials from 1966 to 2007 demonstrated a 41% reduction in stroke 
for a BP reduction of 10 mmHg systolic or 5 mmHg diastolic regardless of BP before 
treatment (down to 110 mmHg systolic and 70 mmHg diastolic), similar to 36% reductions 
expected for the same difference in BP from the cohort study meta-analysis [5]. The 
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percentage reductions in coronary heart disease (CHD) events and stroke also were similar 
in people with and without cardiovascular disease (CVD) [5].
Although there is an agreement that BP >140/90 mmHg should be treated, the ideal BP 
target has not been established [6–8], and the definitive evidence confirming that any class 
of antihypertensive agents offers special protection against stroke is lacking [4,5]. In 
addition, the results of several recent studies showed that lower BP levels may not always 
result in better outcomes in patients with diabetes or clinically manifest vascular disease. 
The data from the ACCORD BP trial showed that achieving a systolic BP below 120 mmHg 
compared with standard therapy of targeting below 140 mmHg among subjects with 
diabetes mellitus or those with impaired fasting glucose/glucose tolerance reduced the risk 
of stroke but not composite cardiovascular events [9]. The author of a meta-analysis of 13 
clinical trials published in 2011 concluded that in patients with Type 2 diabetes mellitus/
impaired fasting glucose/impaired glucose tolerance, a systolic BP treatment goal of 130 to 
135 mmHg remains acceptable [10]. The continued risk reduction for stroke to a systolic BP 
of <120 mmHg was reported among these patients, however, there was a 40% increase in 
serious adverse events with no benefit for other outcomes at levels <130 mmHg 
(macrovascular or microvascular [cardiac, renal and retinal events]).
Several recent studies also investigated the association between achieving systolic BP <140 
mmHg and risk of CVD events or total mortality among patients with pre-existing CVD. In 
a multicenter prospective study of patients with recent noncardioembolic ischemic stroke, 
the very low–normal (systolic BP <120 mmHg) compared with the high–normal (systolic 
BP 130–139 mmHg) BP was associated with increased risk of stroke (hazard ratio [HR]: 
1.29; 95% CI: 1.07–1.56) [11]. In another observational post hoc analysis of patients with 
coronary artery disease and Type 2 diabetes mellitus from the INVEST study, no nonfatal or 
stroke-risk reduction was observed among patients with a systolic BP below 130 mmHg 
compared with patients with a systolic BP from 130 to 140 mmHg [12]. In the ONTARGET 
trial, which included patients at high CVD risk, an increased frequency of BP control to 
<140/90 or <130/80 mmHg was associated with a progressive reduction in the risk of stroke, 
new onset of microalbuminuria or macroalbuminuria, and the return to normoalbuminuria in 
albuminuric patients [13]. However, no consistent effect on the adjusted risk of myocardial 
infarction and heart failure were observed in this study and achieving the <130/80 mmHg 
target had little effect on the adjusted risk of overall cardiovascular events or cardiovascular 
mortality [13]. The results of a meta-analysis that included 25 clinical trials showed that 
antihypertensive treatment was associated with a 23% decreased risk of stroke among 
patients with a clinical history of CVD but without hypertension [14]. However, only a few 
studies included in this meta-analysis reported baseline BP levels and, thus, the associations 
between BP levels and risk of first occurrence or recurrence of CVD events can not be 
evaluated [14]. As the authors noted, the observed benefit associated with use of 
antihypertensive treatment may have been attributable to BP lowering as well as to other 
tissue or neurohormonal mechanisms [14]. Finally, although 35% reduced risk of stroke was 
observed in a meta-analysis of randomized controlled trials among hypertensive patients 80 
years of age and older with or without pre-existing CVD, an inverse relationship between 
total mortality and higher intensity of antihypertensive treatment was reported [15].
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Concerns also have been raised that lowering diastolic BP below optimal (80 mmHg) may 
increase the risk for coronary events by impairing coronary perfusion, especially in elderly 
patients, patients with left ventricular hypertrophy and/or coronary heart disease and with a 
wide pulse pressure [16]. By contrast, findings from a recent review did not find enough 
evidence to support a J-shaped curve relationship of low diastolic BP with stroke, pointing 
out that cerebral blood flow may not be substantially affected by low diastolic BP [17].
Dyslipidemia
While the relationship between lipids and CHD is well established, results from 
observational studies examining the associations between lipid profile and stroke are less 
conclusive. In a meta-analysis of long-term prospective studies, mostly in Europe and North 
America, low-density lipoprotein cholesterol (LDL-C) was only modestly related to 
ischemic stroke and unrelated to hemorrhagic stroke [18]. Similar results were found in a 
binational study in Northern Ireland and France [19]. The relationship between serum LDL-
C and ischemic stroke varies by type of ischemic stroke. Although a significant and positive 
association was found for atherothrombotic infarctions, a negative significant association 
was observed for cardioembolic infarction [20].
The inverse associations of blood total cholesterol as well as LDL-C concentrations with 
hemorrhagic stroke found in some studies have raised concern that intensive therapy with 
lipid-lowering medication that result in low LDL-C levels may increase risk of hemorrhagic 
stroke [21]. However, evidence indicates that low LDL-C levels achieved during intensive 
statin treatment, are not significantly associated with an increased risk for hemorrhagic 
stroke, except in patients with a history of intracerebral hemorrhagic stroke [22,23]. 
Furthermore, findings from both the 2006 [22] and 2010 meta-analyses [23] of patients 
using statin therapy, show that reduction in LDL-C by 1 mmol/l (39 mg/dl) results in a 
decreased incidence of ischemic stroke by 16–17% regardless of age, BP and pretrial blood 
lipid profile. In the second 2010 meta-analysis, the risk of total stroke was decreased 
significantly by treatment of statins, with each 1% reduction of total cholesterol predicting a 
0.8% relative risk [RR] reduction of total stroke [24]. Moreover, in nonsystematic review, 
pretreatment with statins in patients with ischemic stroke was associated with lower stroke 
severity with a better protective effect observed in atherothrombotic and lacunar infarctions. 
However, discontinuation of statin treatment during acute stroke is associated with loss of 
the protective effect and with higher mortality at 1 year of follow-up [25].
Fibrates have been shown to be effective in raising high-density lipoprotein cholesterol 
(HDL-C) and lowering triglyceride concentrations, and could potentially reduce LDL-C and 
chylomicron remnants [26]. However, a recent meta-analysis of 18 randomized clinical trials 
did not find a significant association between the use of fibrates and the decreased risk of 
stroke [27]. According to the results of a pooled meta-analysis of six randomized placebo-
controlled clinical trials among patients with Type 2 diabetes mellitus, fibrates did not 
decrease the risk of stroke [28]. Finally, the results of a meta-analysis of the five large trials 
assessing the impact of fibrates on cardiovascular end points demon strated a larger risk 
reduction (by 28%; 95% CI: 15–39%; or 30%; 95% CI: 19–40%, in patients with high 
triglyceride levels (>200 mg/dl) or atherogenic dyslipidemia (HDL-C <35 and tri glycerides 
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>200 mg/dl) respectively, compared with nonatherogenic dyslipidemia patients (by 6%; 
95% CI: 2–13%) [29].
In the 2009 systematic review of five studies, two studies showed a significant inverse 
relationship between HDL-C and stroke mortality in all subpopulations studied, while in 
three studies the association in any subpopulations studied were nonsignificant. The 
associations between HDL-C and subsequent stroke events were also inconsistent: six 
studies showed a significant inverse relationship in all subpopulations studied, one study 
found a significant inverse association in some subpopulations, whereas four studies did not 
find any statistically significant association [30].
Diabetes mellitus
Diabetes is another risk factor for stroke. Findings from the 2010 meta-analysis of 102 
prospective studies showed that diabetes is associated with an approximately twofold 
increased risk for all types of stroke [31]. Furthermore, a review of clinical trials show that 
early aggressive insulin management among younger individuals with Type 1 diabetes 
reduces stroke incidence, but not among older patients with long-term Type 2 diabetes [32]. 
The intensive glucose-lowering therapy (a glycated hemoglobin [HbA1c] level <7.0%) has 
been shown to decrease the risk of microvascular complications and may or may not be 
beneficial for long-term reduction in the risk of CVD [33].
The results of recent clinical trials support treatment of diabetic patients with hypertension 
with an renin–angiotensin system blocking agent (angiotensin-converting enzyme inhibitors 
and angiotensin II receptor blocker) combined with a calcium channel blockers or a thiazide-
type diuretic [34]. The growing number of clinical trials favors renin–angiotensin system 
blocking agent/calcium channel blockers combinations in risk reduction of major fatal and 
nonfatal cardiovascular events as compared with diuretic-based combinations in these 
patients [34].
Atrial fibrillation
Atrial fibrillation (AF) is a common, well-established and strong cardiac risk factor for 
ischemic stroke [35]. AF has been shown to independently increase the risk of stroke by 
two- to ten-times among all age groups [35,36]. Since the prevalence of AF increases with 
age from 1% in the population aged under 50 years to approximately 10% of those above 80 
years, AF accounts for 10–15% of all ischemic strokes and nearly a quarter of strokes in 
patients aged 80 and over in the UK [35]. The risk of stroke among patients with paroxysmal 
(self-terminating) and persistent (lasting more than 7 days or requiring intervention to 
terminate) AF is similar to that for patients with permanent AF (permanent AF is AF that 
either does not respond to cardioversion, surgery or medication, or a decision has been made 
to leave a patient in AF) [35]. Furthermore, compared with stroke patients without AF, 
patients with AF have higher mortality and morbidity, greater disability and longer 
hospitalization [35].
The optimal treatment control strategy – rate versus rhythm – remains controversial since 
both strategies result in reducing mortality or stroke [37]. The results of a recent study 
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showed that rate control is less costly and more effective than rhythm control among 
patients with coexisting heart failure [38]. The efficacy of anticoagulation therapy among 
patients with AF for prevention of stroke and thromboembolism is also well established. The 
current clinical guidelines recommend an individualized anticoagulation therapy for patients 
based on age, comorbidities, contraindications and personal stroke risk [35,39–42]. The 
recently issued guidelines for the primary prevention of stroke by the AHA/ASA guidelines 
recommend the adjusted-dose warfarin (target international normalized ratio: 2.0–3.0) for all 
high-risk patients at with nonvalvular atrial fibrillation [4]. Antiplatelet therapy with aspirin 
is recommended for low-risk patients. The choice of therapy for moderate-risk patients 
between anticoagulation and antiplatelet therapy is based on patient preference, estimated 
bleeding risk if anticoagulated and access to high-quality anticoagulation monitoring [4]. 
For high-risk patients with atrial fibrillation who were deemed unsuitable for anticoagulation 
therapy, dual antiplatelet therapy with clopidogrel and aspirin is suggested [4]. Finally, since 
the use of vitamin K antagonists including warfarin is complicated by numerous food and 
drug interactions and the need for regular coagulation monitoring, novel anticoagulants 
targeting factors IIa (dabigatran) and Xa (rivaroxaban, apixaban, edoxaban) in the 
coagulation cascade have been developed [43]. These novel anticoagulants have been shown 
to be as effective as warfarin with similar or even enhanced safety [43].
Cigarette smoking
Smoking, an established and modifiable risk factor for stroke [44], accounts for 15–50% of 
stroke, depending on age, gender, stroke subtypes and study population [45,46]. Cigarette 
smoking increases the RR approximately twofold and threefold for ischemic stroke and 
subarachnoid hemorrhage, respectively [45]. The strongest association between smoking and 
stroke was observed among female smokers, especially among those who take oral 
contraceptives and have migraine with aura [45]. Moreover, the risk of stroke grows with 
the number of cigarettes smoked (odds ratio [OR] increasing from 2.2 to 2.5, 4.3 and 9.1 for 
consumption of 1–10, for 11–20, for 21–39, and for 40 or more cigarettes smoked per day, 
respectively) [47], but may disappear within the first 5 years after cessation of cigarette 
smoking [48]. The risk of stroke among smokers tends to peak at middle age and declines 
with advancing age; the largest benefits of smoking cessation have been observed among 
individuals before the age of 30 years, because they can potentially have a life expectancy 
similar to nonsmokers [49]. Finally, evidence is accumulating that second-hand (passive) 
smoking increases risk of stroke: pooled estimates of 16 studies showed that passive 
smoking increases risk of stroke by 25% and this risk may reach up to 52% with increased 
exposure [50].
Obesity
In the 2010 systematic review and meta-analysis of 25 prospective studies, the crude 
unadjusted RR of ischemic stroke compared with normal weight was 1.22 (95% CI: 1.05–
1.41) for overweight and 1.64 (95% CI: 1.36–1.99) for obese individuals, whereas crude 
unadjusted RR for hemorrhagic stroke was smaller in magnitude and was borderline 
significant only for the obese (RR: 1.01; 95% CI: 0.88–1.17 for overweight and RR: 1.24; 
95% CI: 0.99–1.54 for obese individuals) [51]. The authors stated that unadjusted estimates 
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of the association minimized the risk of overadjustment for related factors, such as age, 
hypertension, diabetes, dyslipidemia, sedentary lifestyle and abuse of alcohol that are 
components of the pathway between overweight and stroke. However, the results of the 
multivariate estimates were qualitatively similar but the strength of the association with risk 
of ischemic stroke was attenuated for both overweight (RR: 1.18; 95% CI: 1.08–1.28) and 
obese individuals (RR: 1.50; 95% CI: 1.34–1.67), whereas the associations with 
hemorrhagic stroke were statistically nonsignificant (RR: 1.14; 95% CI: 0.96–1.37, for 
overweight) or borderline significant (RR: 1.34; 95% CI: 1.01–1.79, for obesity). 
Participants with high waist-to-hip ratio (WHR; >0.96 cm in men and >0.93 cm in women), 
compared with participants with low WHR (<0.91 cm in men and <0.86 cm in women) had 
an increased risk of 65% (OR: 1.65; 95% CI: 1.36–1.99) and approximately 25% of stroke 
(PAF: 26.5%; 95% CI: 18.8–36.0) was attributable to abdominal obesity in the in the 
INTERSTROKE study [3]. The ARIC Study, among participants in the USA aged 45–65 
years with a median follow-up of 16.9 years were not included in the 2010 meta-analysis 
[51] owing to timing of publication [52]. Results indicated that obesity, regardless of the 
measure (BMI, waist circumference and WHR) was a risk factor for ischemic stroke [52]. 
There was no statistically significant difference in the association between obesity and the 
risk of stroke by race or sex [52]. Adjustment for diabetes and hypertension significantly 
attenuated these associations, suggesting that these factors may account for the majority of 
the risk of stroke that is associated with obesity. Furthermore, subsequent analysis of these 
data by subtypes of ischemic stroke demonstrated that the incidence of lacunar, nonlacunar 
and cardio embolic stroke were all significantly positively associated with the degree of 
obesity, regardless of the measure used to assess obesity (BMI, waist circumference and 
WHR) [53].
A recent prospective observational study showed that obese (HR: 0.71; 95% CI: 0.59–0.86) 
and overweight (HR: 0.82; 95% CI: 0.71–0.94) stroke patients had significantly better 10-
year survival rates compared with those with a normal BMI [54]. Data from clinical trials 
evaluating the impact of purposeful weight reduction on outcome after stroke are not 
available and assessment of markers of body fat distribution and changes in bodyweight 
during follow-up may provide further insight into this paradox.
Diet
Several studies have reported that foods rich in vitamins B, C and E may be beneficial in 
reducing the risk of stroke and improving the post-stroke-associated functional declines. 
However, current available evidence from both observational and intervention studies is 
insufficient to recommend supplementation of these for the prevention of stroke [55]. The 
2010 meta-analysis of nine randomized controlled trials investigating the effect of vitamin E 
on incident stroke concluded that vitamin E supplementation increased the risk for 
hemorrhagic stroke by 22% and reduced the risk of ischemic stroke by 10%. The authors 
cautioned against widespread use of vitamin E supplementation [56].
The relationship between saturated fat intake and stroke remains controversial. In a recent 
systematic review, dietary intake of saturated fat did not appear to increase the risk of stroke, 
and a protective effect was demonstrated in some studies [57]. Similar results were found in 
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a meta-analysis of eight prospective studies, where the pooled estimate for associations 
between dietary saturated fat intake (high vs low quantiles) and an increased risk of stroke 
(RR: 0.81; 95% CI: 0.62–1.05) did not reach significance [58]. On the other hand, a large 
community-based prospective cohort study in Japan, found that compared with low dietary 
intake of saturated fat (9.2 g/day), high intake (20.3 g/day) was inversely associated with 
mortality from total stroke (RR: 0.69; 95% CI: 0.53–0.89), intraparenchymal hemorrhage 
(RR: 0.48; 95% CI: 0.27–0.85), and ischemic stroke (RR: 0.58; 95% CI: 0.37–0.90), but not 
for subarachnoid hemorrhage (RR: 0.91; 95% CI: 0.46–1.80) [59]. Sodium is another 
nutrient potentially associated with stroke. Strong evidence shows that higher sodium intake 
results in higher BP levels, but not necessarily stroke or mortality [60]. Nevertheless, the 
pooled estimates obtained from the 2009 meta-analysis of 19 independent cohort samples 
from 13 studies showed that higher sodium intake was indeed associated with a greater risk 
of stroke (RR: 1.23; 95% CI: 1.06–1.43), and a higher magnitude observed in studies with a 
larger range of sodium intake and a longer follow-up period [61].
Compared to single nutrients, the quality and variety of the entire diet may be a stronger 
predictor of cardiovascular mortality and morbidity. In the 2009 INTERSTROKE study, 
dietary patterns measured by diet risk score using a simple 19-item qualitative food group 
frequency questionnaire was consistently associated with ischemic, intracerebral 
hemorrhagic, all stroke (increased risk 29, 53, 35% for highest vs lowest tertile, 
respectively) and accounted almost for 20% of all stroke [3]. The results of this study also 
indicate that increased consumption of fruits and fish was associated with reduced stroke 
risk, whereas red meat, organ meats, eggs, fried foods, pizza, salty snacks and cooking with 
lard was associated with an increased risk of stroke [3]. Adherence to four a priori-defined 
dietary patterns: Healthy Eating Index 2005 (HEI-2005), Dietary Approaches to Stop 
Hypertension (DASH), Greek Mediterranean Index and Italian Mediterranean Index, was 
significantly inversely associated with risk of all types of stroke (except for HEI) and risk of 
ischemic stroke (except the Greek Index) in a large longitudinal study (more than 40,000 
participants) from Italy [62]. In addition, according to a recent nonsystematic review, tea 
drinking and consumption of soy foods and dairy products decreases risk of stroke while 
consumption of rice-based foods increase the risk of stroke [63]. Finally, participants with 
the highest levels of chocolate consumption had a 29% reduction in stroke compared with 
participants with the lowest levels in a meta-analysis of seven observational studies [64].
Although no significant association was found with vegetable intake in the INTERSTROKE 
study, the 2006 meta-analysis of eight observational studies found a significant protective 
effect against stroke of fruit and vegetables intake [65]. This effect had a dose–response 
realtionship: compared with individuals who had less than three servings of fruit and 
vegetables per day, those with three to five and those with more than five servings per day 
had an 11 and 26% lower RR of stroke, respectively [65]. Furthermore, subgroup analyses 
showed that fruit and vegetables had a significant protective effect on both ischemic and 
hemorrhagic stroke [65]. The models-based study showed that achieving the recommended 
consumption of five portions of fruits and vegetables of a day in the UK is likely to offer the 
most benefit for stroke mortality compared with achieving dietary targets for sodium and 
saturated fat [66]. Finally, it should be noted that the results of all stroke-related nutritional 
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studies should be interpreted with caution owing to the inherent limitations of dietary 
assessment and variability of stroke end points that were included in these studies [67].
Alcohol intake
The role of alcohol intake as a risk factor for stroke has been widely studied. Current 
epidemiological data shows that associations between alcohol intake and stroke vary 
depending on the amount of alcohol consumed and type of stroke [68]. Light-to-moderate 
drinking in observational studies decreased the risk of CHD, ischemic stroke and diabetes 
mellitus. Moderate consumption of wine has been shown to be more protective against CHD 
than moderate consumption of liquor or beer [68]. This may be due to the nonalcohol 
beneficial components in wine (especially red wine), but also may be due to a different 
pattern of drinking or more favorable risk profiles among wine drinkers.
Regular heavy alcohol intake seems to increase the risk of hemorrhagic stroke while light-
to-moderate drinking may have a protective effect for ischemic stroke [68,69]. Binge 
drinking was found to increase the risk of any type of stroke. The results of a recent Korean 
study showed that the relationship between stroke and binge drinking may be modified by 
hypertensive status with markedly increased associations (a 12-fold risk of cardiovascular 
mortality) observed in the hypertensive group vs the normotensive group [70]. In addition, 
according to the results of the 2010 systematic reviews of ten studies, the risk of ischemic 
stroke increased by two- to threefold after alcohol intake within 24 h (>40–60 g = three to 
five drinks) or 1 week (>150 g = 11 drinks), and the strength of the association increases 
with the amount of alcohol [71]. Finally, in the 2011 review of 84 studies of alcohol 
consumption and CVD, alcohol consumption >60 g/day increased the risk of incident stroke 
by 62% compared with abstaining from alcohol [72].
Physical activity
In the 2009 INTERSTROKE study, regular physical activity (PA) was associated with 
approximately 30% of reduced risk of stroke and could prevent approximately 30% of stroke 
regardless of stroke type [3]. According to the results of the 2010 meta-analysis of 13 
studies from 1986 to 2005, increased PA level appears beneficial in reduction of stroke risk 
[73]. Since measurements of the level of PA (mostly self-reported) varied among the studies, 
the authors of the 2010 meta-analysis characterized PA level as low, moderate or high as it 
was reported in the articles or reported in a manner for reclassification. Compared with low 
PA, high PA resulted in a 19% (95% CI: 16–23) and 24% (95% CI: 11–36) reduction in risk 
of stroke among the men and women, respectively [73]. Among the men, results showed a 
12% reduction in risk associated with moderate PA (95% CI: 6–18) but no significant risk 
reduction associated with a moderate PA level in women [73].
Clearly a dose–response relationship between PA and stroke was found in a review study 
[74]. While higher levels (intensity, duration and frequency) of both occupational and 
leisurely PA, have been shown to be significantly protective against stroke, even a moderate 
increase in one’s activity level can have significant benefit in reducing the risk of stroke 
[74]. Finally, although no studies show that increased PA after stroke reduces risk of 
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recurrent stroke, evidence shows that a higher level of PA results in lesser stroke severity 
and a better long-term outcome following stroke [75].
Depression
Although numerous studies have documented a high prevalence of depression (33%) after 
stroke [76], there is growing evidence that depression and depressive symptoms are indeed, 
risk factors for stroke [77]. The 2007 meta-analysis reported that the pooled estimate for 
total stroke was 1.43 (95% CI: 1.17–1.75) [77]. However, these results should be interpreted 
with caution owing to the heterogeneity of the studies. The results of the meta-analysis that 
was published in 2011 were in line with the 2007 meta-analysis [78]. The pooled adjusted 
HRs were 1.45 (95% CI: 1.29–1.63), 1.55 (95% CI: 1.25–1.93) and 1.25 (95% CI: 1.11–
1.40) for total stroke, fatal stroke and ischemic stroke, respectively.
The relationship between stroke and depression may be modified by age. Salaycik et al. did 
not find a significant relationship between depressive symptoms and stroke among adults 
≥65 years [79], two recent studies suggest that depression increases the risk of stroke among 
the elderly [80,81]. In a Swedish study of 494, 85-year-old adults, depression at baseline 
increased the risk of first stroke twofold during a 3-year follow-up (HR: 2.7; 95% CI: 1.5–
4.7), and this relationship remained even after accounting for dementia [80]. Additionally, 
the results from the Cardiovascular Health Study of 5525 men and women aged 65 years and 
older, demonstrated a higher risk between baseline depressive symptoms and ischemic 
stroke (32%) after adjusting for sociodemographic and traditional stroke risk factors; no 
significant risk was found to be associated with hemorrhagic stroke [81]. Findings from 
recent studies suggest a higher risk of morality due to stroke among depressed individuals 
[82,83].
There is some concern as to whether these results are due to depression itself or a result of 
the use of antidepressant medication. Some studies have found that use of antidepressant 
medication did not alter the relationship between depressive symptoms and the increased 
risk of stroke/transient ischemic attack among men and women [79,80]. On the other hand, 
the results from the Women’s Health Initiative prospective cohort study among 
postmenopausal women, demonstrated that antidepressant use, specifically selective 
serotonin reuptake inhibitors, increases the risk of stroke by almost 45% [84].
Psychological distress
Psychological distress encompasses a wide range of emotions that generally impairs daily 
cognitive and social functions; it includes: anxiety, stress, nervousness, frustration and 
general negative moods (excluding depression) [85]. Although only a few studies have 
examined the relationship between psychological distress and incidence of stroke, evidence 
indicates that psychological distress is a significant risk factor for stroke [86–89]. Among 
20,627 participants aged 41–80 years in the UK EPIC-Norfolk study, the risk for stroke for a 
one standard deviation decrease of the Mental Health Inventory (MHI-5 scale) score 
(representing higher emotional distress) assessed at baseline, was 11%; and conformed to a 
dose–response relationship [87]. This association remained the same for men and women, 
however it was more pronounced for fatal stroke (22%). In addition, using the general health 
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questionnaire to measure psychological distress, researchers found that middle-aged men 
(45–59 years) enrolled in the Caerphilly study, had a higher risk of fatal ischemic stroke 
(45%), but not nonfatal stroke or transient ischemic attack [90].
Furthermore, evidence indicates that self-perceived psychological stress was associated with 
higher risk of stroke (3.49; 95% CI: 2.06–5.93) [89]. One study even found that 
occupational stress associated with job strain increased the risk of stroke by twofold [86]. In 
a systematic review of 26 studies published between January 1980 and June 2010 from 
MEDLINE and Embase, anger (OR: 14; 95% CI: 2.8–253.6), negative (OR: 14; 95% CI: 
4.4–89.7) or positive emotions (OR 4.0; 95% CI: 1.0–26.5), sudden posture change in 
response to a startling event (OR: 24; 95% CI: 5.1–428.9), birthdays (OR: 1.3; 95% CI: 1.1–
1.5) and psychological distress (OR: 3.9; 95% CI: 1.8–8.4) were among significant triggers 
of ischemic stroke [71].
Expert commentary & five-year view
Although there is considerable variation in stroke incidence and mortality across countries, 
approximately 90% of stroke deaths occur in low- and middle-income countries (including 
much of Eastern Europe, Russia, China, India, Nigeria and Tanzania) and are expected to 
increase in low-income countries owing to increases in the prevalence of risk factors for 
CVD, including urbanization and Western-style dietary changes [1]. In China alone, there 
were 7 million strokes in 2005 [91] and predictions estimate a more than 50% increase in 
CVD events (including stroke) in China between 2010 and 2030 [92]. Stroke is the leading 
cause of cardiovascular mortality among adults 40 years and older in China, claiming 277 
lives per 100,000 person-years, compared with CHD at 85 per 100,000 person-years [93]. In 
2005, stroke-related deaths in China accounted for approximately a fourth of total deaths 
from stroke in the world [94].
Poor management of hypertension may be one of the major factors contributing to the 
disparity in stroke incidence and mortality between low- or middle- and high-income 
regions. Hypertension control rate among hypertensive patients was reported as low as 2–
4% in population-based studies of Chinese adults [95,96]. The limited availability of 
healthcare providers, budgetary constraints for the majority of population, and the problem 
that drugs are not in stock are among additional factors contributing to poor control of 
hypertension in middle- and low-income countries [97]. Although smoking among males 
has declined by more than 10% since the mid-1980s, approximately 60% of Chinese men 
continue to smoke, and at least 50% of nonsmokers (predominantly women) are exposed to 
self-reported passive smoking [92]. Moreover, it has been estimated that this rate of decline 
in smoking will not be sufficient to counteract approximately 26 million CVD events and 9 
million cardiovascular deaths added by deleterious trends in high BP, high cholesterol, 
diabetes and obesity [92]. The estimated number of cardiovascular events (CHD and stroke) 
in adults aged 35–84 years is projected to double by 2030, given the aging, growing 
population and increase in stroke risk factors [92]. The changes in CVD risk profile at the 
population level may not only contribute to increasing trends in stroke, especially among 
young adults but also to changes in the predominance of hemorrhagic stroke to ischemic 
stroke [98]. Similar concerns apply to many other low- and middle-income countries. 
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International examples of successful population-level efforts across the world to address risk 
factors for stroke such as hypertension (including sodium consumption), tobacco use, 
excessive alcohol consumption, lack of healthy dietary options exist. Further work is 
required to reduce these significant but modifiable contributors to the global burden of 
stroke, especially where the burden of stroke is greatest – low- to middle-income countries. 
In addition to to public health challenges in prevention [46], challenges in monitoring, 
studying and treating stroke, including the lack of available imaging such as CT scans, and 
use of advanced care techniques, substantially slow down the progress in reducing stroke-
related mortality and morbidity in low- and middle-income countries.
The described ten traditional risk factors in this review are major contributing factors for 
stroke for most populations [3,4]. However, none of these risk factors have been studied in 
some populations, especially young children and young adults aged <45 years. Several 
longitudinal studies showed that CVD risk factors presenting during childhood may persist 
into adulthood and adoption of healthy lifestyle behaviors appears to be promising as a 
counteractive force [99,100]. Consistent with these findings, the results from the US national 
population-based cohort demonstrated that adolescence or early adulthood exposure may be 
a stronger predictor of lifetime development of hypertension than exposures at other times 
[101].
Finally, several other modifiable risk factors may be less important for population-level 
interventions owing to a relatively low prevalence or moderate associations with stroke but 
may be of great importance for the individual patient. In the Guidelines for the Primary 
Prevention of Stroke for Healthcare Professionals from the AHA/ASA, they were classified 
as well-documented and less well-documented [4]. The well-documented factors included 
certain cardiac conditions, carotid artery stenosis, sickle cell disease and postmenopausal 
hormone therapy. Drug abuse, use of oral contraceptives, sleep-disordered breathing, 
migraine, hyperhomocysteinemia, hypercoagulability, inflammation and infection were 
listed as the less well-documented risk factors. Future studies focusing on these risk factors 
and their role in the pathogenesis of stroke, as well as assessing concurrently several risk 
factors, are needed to develop effective interventions and programs for prevention of stroke 
at population level.
The current evidence supports addressing the ten major modifiable risk factors for stroke. 
The international scientific and public health community recognized that a population-level 
intervention focused on tobacco control and ultimate elimination, reduction of sodium 
intake, promotion of a healthy diet low in saturated fats and sugar, reduction in the 
consumption of alcohol, and increased PA would be the most cost-effective way to address 
the fast-growing epidemic of noncommunicable diseases including CVD [102].
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• Hypertension, diabetes, current smoking, atrial fibrillation, abdominal obesity, 
poor diet, physical inactivity, heavy alcohol consumption, abnormal lipid profile 
and psychosocial stress/depression are recognized as major population-level risk 
factors for stroke. Although there is an agreement that blood pressure (BP) 
>140/90 mmHg should be treated, the ideal BP target has not been established 
and the definitive evidence confirming that any class of antihypertensive agents 
offers special protection against stroke is lacking.
• The results of several recent studies showed that lower BP levels may not 
always result in better outcomes in patients with diabetes or clinically manifest 
vascular disease.
• Current evidence supports treatment of diabetic patients with hypertension with 
a calcium-channel blocker combined with blockers, angiotensin converting 
enzyme inhibitors or angiotensin II receptor, as compared with diuretic-based 
combinations in risk reduction of major fatal and nonfatal cardiovascular events.
• The adjusted-dose warfarin for all high-risk patients with nonvalvular atrial 
fibrillation is recommended. Antiplatelet therapy with aspirin is recommended 
for low-risk patients. Novel anticoagulants (dabigatran, rivaroxaban, apixaban 
and edoxaban) that do not require regular coagulation monitoring have been 
shown to be as effective as warfarin with similar or even enhanced safety.
• Reduction in low-density lipoprotein cholesterol by 1 mmol/l (39 mg/dl) using 
statin therapy results in a decreased incidence of ischemic stroke by 16–17%.
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